Group by: Creators | Item Type
Jump to: B | D | I | M | N | P | R | W | X | Y
Number of items at this level: 18.

B

Band, S and Gilchrist, FJ ORCID: https://orcid.org/0000-0002-1947-7621 (2021) Lupus vulgaris and disseminated BCG. Archives of Disease in Childhood, 107 (2). p. 203.

Bechman, K, Cook, ES, Dand, N, Yiu, ZZN, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Bachelez, H, Barbosa, I, Brown, MA, Capon, F, Contreras, CR, De La Cruz, C, Di Meglio, P, Gisondi, P, Jullien, D, Kelly, J, Lambert, J, Lancelot, C, Langan, SM, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, McAteer, H, Moorhead, L, Naldi, L, Norton, S, Puig, L, Spuls, PI, Torres, T, Urmston, D, Vesty, A, Warren, RB, Waweru, H, Weinman, J, Griffiths, CM, Barker, JN, Smith, CH, Galloway, JB, Mahil, SK and study group, PsoProtect (2022) Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. British Journal of Dermatology.

D

Dand, N, Duckworth, M, Baudry, D, Russell, A, Curtis, CJ, Lee, SH, Evans, I, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Alsharqi, A, Becher, G, Burden, AD, Goodwin, RG, McKenna, K, Murphy, R, Perera, GK, Rotarescu, R, Wahie, S, Wright, A, Reynolds, NJ, Warren, RB, Griffiths, CEM, Smith, CH, Simpson, MA, Barker, JN, Study Group, BADBIR, Study Group, BSTOP and Consortium, PSORT (2018) HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143 (6). 2120 - 2130.

I

Iskandar, IYK, Warren, RB, Lunt, M, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Evans, I, McElhone, K, Smith, CH, Reynolds, NJ, Ashcroft, DM, Griffiths, CEM and Study Group, BADBIR (2017) Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138 (4). 775 - 784.

M

Mahil, SK, Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Dand, N, Coker, B, Wall, D, Fletcher, G, Bosma, A, Capon, F, Iversen, L, Langan, SM, Di Meglio, P, Musters, AH, Prieto-Merino, D, Tsakok, T, Warren, RB, Flohr, C, Spuls, PI, Griffiths, CEM, Barker, J, Irvine, AD and Smith, CH (2020) Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 183 (2). 404 - 406.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Barker, JNWN, Smith, CH, Hampton, PJ, Lunt, M, McElhone, K, Warren, RB, Yiu, ZZN, Griffiths, CEM, Burden, AD and Study Group, BADBIR (2018) Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 154 (5). 581 - 588.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Williams, S, Yiu, ZZN, McElhone, K, Ashcroft, DM, Kleyn, CE, Jabbar-Lopez, ZK, Owen, CM, Reynolds, NJ, Smith, CH, Wilson, N, Warren, RB and Griffiths, CEM (2019) Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. British Journal of Dermatology, 181 (2). 256 - 264.

Moss, GPJ, Sun, Y, Davey, N, Wilkinson, SC and Brown, MB (2015) Linear or non-linear models for percutaneous absorption? International Journal Of Cosmetic Science, 37 (1). 144 -144.

N

Nelson, PA, Barker, Z, Griffiths, CEM, Cordingley, L and Chew-Graham, CA (2013) 'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis. BMC Family Practice, 14. 158 -?.

P

Pan, S, Tsakok, T, Dand, N, Lonsdale, DO, Loeff, FC, Bloem, K, de Vries, A, Baudry, D, Duckworth, M, Mahil, S, Pushpa-Rajah, A, Russell, A, Alsharqi, A, Becher, G, Murphy, R, Wahie, S, Wright, A, Griffiths, CEM, Reynolds, NJ, Barker, J, Warren, RB, David Burden, A, Rispens, T, Standing, JF, Smith, CH and Study Group, the BSTOP Study Group, the PSORT Consortium, BADBIR (2020) Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. Clinical and Translational Science, 13 (2). 400 - 409.

Polidano, K, Parton, L, Agampodi, S, Agampodi, T, Haileselassie, B, Lalani, J, Mota, C, Price, HP ORCID: https://orcid.org/0000-0003-1537-4390, Rodrigues, S, Tafere, G, Trad, L, Zerihun, Z and Dikomitis, L ORCID: https://orcid.org/0000-0002-5752-3270 (2022) Community engagement in cutaneous leishmaniasis research in Brazil, Ethiopia, and Sri Lanka: a decolonial approach for global health. Frontiers in Public Health, 10.

R

Rungapiromnan, W, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, McElhone, K, Burden, AD, Rutter, MK, Warren, RB, Griffiths, CEM, Ashcroft, DM and Study Group, BADBIR (2019) Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34 (4). 769 - 778.

Rungapiromnan, W, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, McElhone, K, Rutter, MK, Warren, RB, Griffiths, CEM, Ashcroft, DM and Grp, BADBIRS (2019) Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Pharmacoepidemiology and Drug Safety, 27. 467 - 467.

W

Warren, RB, Marsden, A, Tomenson, B, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Soliman, MM, Burden, AD, Reynolds, NJ, Stocken, D, Emsley, R, Griffiths, CEM, Smith, C, Consortium, PSORT and Study Group, BADBIR (2018) Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180 (5). 1069 - 1076.

X

Xu, X, van Galen, L, Bajpai, R ORCID: https://orcid.org/0000-0002-1227-2703, Koh, M, Thng, S, Yew, Y, Järbrink, K and Car, J (2020) Factors Influencing Family Burden of Paediatric Patients with Atopic Dermatitis: A Cross-sectional Study. Acta Dermato Venereologica.

Y

Yiu, ZZN, Ashcroft, DM, Evans, I, McElhone, K ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, Smith, CH, Walton, S, Murphy, R, Reynolds, NJ, Ormerod, AD, Griffiths, CEM, Warren, RB and Study Group, BADBIR (2018) Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 180 (2). 329 - 337.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Barker, JNWN, Hampton, PJ, McElhone, K, Smith, CH, Warren, RB, Griffiths, CEM, Lunt, M, Burden, AD and Study Group, BADBIR (2019) A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 181 (6). 1265 - 1271.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Hampton, PJ, Reynolds, NJ, Smith, CH, Lunt, M, Griffiths, CEM and Warren, RB (2020) Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 183 (2). 294 - 302.

This list was generated on Thu Dec 1 06:11:37 2022 UTC.